Castle Biosciences to Present at Baird Global Healthcare Conference on Sept. 10.
ByAinvest
Thursday, Aug 21, 2025 7:03 am ET1min read
CSTL--
Additionally, Castle Biosciences' executive management will be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on September 11, 2025. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets [1].
Castle Biosciences aims to transform disease management by providing innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett’s esophagus, and uveal melanoma. They also have active research and development programs for tests in these and other diseases with high clinical need [1].
Recently, Derek J. Maetzold, President & Chief Executive Officer and Director at Castle Biosciences, sold 43,019 shares of Common Stock on August 13, 2025, at a weighted average price of $19.504 per share, totaling $839,042. Following the transaction, Maetzold directly owns 69,683 shares and indirectly owns 261,372 shares through various trusts [2].
References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html
[2] https://www.tradingview.com/news/tradingview:2cf6a17818acc:0-castle-biosciences-ceo-derek-j-maetzold-sells-shares/
Castle Biosciences announced that its executive management will present a company overview at Baird's 2025 Global Healthcare Conference on Sept. 10, 2025. The presentation will be live-streamed on the company's website. The executive team will also be available for one-on-one investor meetings during the Wells Fargo and Lake Street Capital Markets conferences on Sept. 4 and Sept. 11, respectively.
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, has announced its participation in several upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10, 2025, at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website [1].Additionally, Castle Biosciences' executive management will be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on September 11, 2025. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets [1].
Castle Biosciences aims to transform disease management by providing innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett’s esophagus, and uveal melanoma. They also have active research and development programs for tests in these and other diseases with high clinical need [1].
Recently, Derek J. Maetzold, President & Chief Executive Officer and Director at Castle Biosciences, sold 43,019 shares of Common Stock on August 13, 2025, at a weighted average price of $19.504 per share, totaling $839,042. Following the transaction, Maetzold directly owns 69,683 shares and indirectly owns 261,372 shares through various trusts [2].
References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html
[2] https://www.tradingview.com/news/tradingview:2cf6a17818acc:0-castle-biosciences-ceo-derek-j-maetzold-sells-shares/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet